News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ignyta Announces Effectiveness Of Form S-1 Resale Registration Statement


2/12/2014 8:06:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that on February 11, 2014, the Securities and Exchange Commission declared effective the company’s registration statement on Form S-1 relating to resale of up to 9,010,238 shares of Ignyta’s common stock, par value $0.00001 per share, by certain selling stockholders. The company registered these shares to satisfy commitments it made in connection with the raising of approximately $54 million in equity financing to certain institutional investors and high net worth individuals.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Ignyta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES